Last May, Gilead Sciences (GILD) chief executive Daniel O’Day testified before Congress that a revised version of a best-selling HIV pill was a “brand new medicine” and that the company was “absolutely not” aware it was safer than an older version during the early stages of development.
Yet a recently filed lawsuit offers details that purportedly contradict his remarks and, in the process, raises questions about the extent to which Gilead may have deliberately delayed bringing a new treatment to market in order to milk sales of an older, lucrative franchise.
About the Author Reprints
I was in a meeting in the early 2000’s in San Francisco when they mentioned TAF. A few years later they did not want to mention it again.
In some better society in a future that we only dream about sick people will not be abused by greedy people.